Multi-modality Imaging in Peritoneal Carcinomatosis of Colorectal Origin

• Status: Unknown status
• Trial end date: 2021-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Intraoperative tumor localization and resection can be enhanced using intraoperative fluorescence imaging and radiodetection. Labetuzumab specifically recognizes CEA which is is expressed on > 95% of colorectal cancers.. Therefore Indium-111-DOTA-labetuzumab-IRDye800CW is a perfect dual-labeled antibody for dual-modality image-guided surgery in peritoneal carcinomatosis of colorectal cancer.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Radboud University
• Collaborators: Dutch Cancer Society; KWF
• Treatments: Labetuzumab

Criteria

Inclusion Criteria:

• Clinical diagnosis of peritoneal carcinomatosis of colorectal origin

• Scheduled for cytoreductive surgery and HIPEC.

• Age over 18 years

• Signed informed consent

Exclusion Criteria:

• Any medical condition present that in the opinion of the investigator will affect patients clinicals status

• Administration of a radionuclide within 10 physical half-lives prior to study enrollment

• Pregnancy or lactation

• Patients with very high (>500ng/ml serum CEA levels

• Known CEA negative tumor